MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MWN-AI** Summary
MediciNova, Inc., a biopharmaceutical company listed on NASDAQ and the Tokyo Stock Exchange, announced the completion of patient enrollment for its Phase 2 clinical trial (MN-001-NATG-202) evaluating MN-001 (Tipelukast) for treating hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD) associated with Type 2 diabetes mellitus (T2DM). The trial features a multi-center, randomized, double-blind, placebo-controlled design where patients are assigned to receive either 500 mg/day of MN-001 or a placebo for 24 weeks. The co-primary endpoints focus on changes in liver fat content and fasting serum triglycerides by Week 24, while secondary endpoints assess safety, tolerability, and lipid profile changes. Top-line data results are anticipated by summer 2026.
Tipelukast is a small, orally bioavailable compound believed to work through multiple mechanisms, including leukotriene receptor antagonism and inhibition of certain enzymes implicated in the inflammatory and fibrotic pathways. This novel approach is especially relevant, given the correlation between hypertriglyceridemia, dyslipidemia, and NAFLD in patients with T2DM, highlighting the urgent need for effective treatments in this patient population.
MediciNova is advancing a range of clinical programs focused on therapeutics for various inflammatory, fibrotic, and neurodegenerative diseases. In addition to MN-001, the company’s lead candidate MN-166 is currently in Phase 3 trials for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy. With a robust pipeline and emphasis on innovative therapies backed by solid safety profiles, MediciNova aims to address pressing medical needs.
However, the company also disclosed that these forward-looking statements encompass various risks, including challenges inherent in clinical trials, funding, and regulatory approvals. Stakeholders are advised to consult recent filings for more detailed information.
MWN-AI** Analysis
MediciNova, Inc.'s recent announcement regarding the completion of patient enrollment in the Phase 2 clinical trial for MN-001 (tipelukast) marks a significant milestone for the biopharmaceutical company as it seeks to address critical unmet medical needs in treating hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD) related to Type 2 diabetes mellitus (T2DM). This phase of the trial lays the groundwork for potential upcoming data releases, making MediciNova an interesting prospect for investors.
With top-line results expected by the summer of 2026, investors should keep a close watch on both market developments in NAFLD treatments and competitor pipelines. The successful demonstration of MN-001's efficacy could position MediciNova favorably in a expanding market, as the prevalence of diabetes and associated complications continues to rise globally. Given the increasing focus on metabolic health, there is a burgeoning demand for innovative therapies like MN-001.
Moreover, MediciNova's strong safety profile and diverse therapeutic approach, including mechanisms targeting leukotriene receptor antagonism, phosphodiesterase inhibition, and anti-inflammatory effects, may give it a competitive advantage in a crowded biopharmaceutical landscape. However, potential investors should also be mindful of inherent risks. The successful progression of clinical trials is not guaranteed, and market reactions to trial data can be volatile.
Furthermore, while management has a track record of securing funding for clinical trials, navigating capital requirements amidst ongoing trials introduces additional uncertainty. A cautious approach is advisable: consider a position in MediciNova, but pursue gradual accumulation rather than large commitments. Given the promising outlook but underpinned by clinical trial risks, prospective investors may wish to monitor trial progress closely and assess broader market conditions in the biopharmaceutical sector before making substantial investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the completion of patient enrollment in its Phase 2 clinical trial, MN-001-NATG-202, evaluating MN-001 (Tipelukast) for the treatment of hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD) due to Type 2 diabetes (T2DM). Patient recruitment is closed.
The MN-001-NATG-202 study is a multi-center, randomized, double-blind, placebo-controlled trial to evaluate MN-001(tipelukast). Patients are randomized 1:1 to receive either 500 mg/day of MN-001 (tipelukast) or placebo for 24 weeks.?The co-primary endpoints are (1) change from baseline in liver fat content measured by controlled attenuation parameter (CAP) score at Week 24, and (2) change from baseline in fasting serum triglycerides at Week 24. Secondary endpoints include safe24 and tolerability and changes in lipid profile (HDL-C, LDL-C, and total cholesterol). Top-line data are expected by the summer of 2026
About MN- 001
MN-001 (tipelukast) is a novel, orally bioavailable, small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterase (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development, and MN-001's inhibitory effect on 5-LO and the 5-LO/LT pathway is a novel approach to treat fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. It also inhibits triglyceride synthesis in hepatocytes by inhibiting arachidonic acid uptake. Recent research suggested that MN-002, the major metabolite of MN-001, significantly enhanced cholesterol efflux in macrophages by upregulating key transport proteins ABCA1 and ABCG1.
About Type 2 Diabetes Mellitus (T2DM), Dyslipidemia and non-alcoholic fatty liver disease (NAFLD)
Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by insulin resistance, which plays a central role in the development of dyslipidemia—abnormal levels of lipids in the blood.?Hypertriglyceridemia (elevated triglycerides) is commonly observed in individuals with T2DM. It results from increased hepatic lipid synthesis and impaired clearance of triglyceride-rich lipoproteins. Hypercholesterolemia, particularly elevated LDL cholesterol and reduced HDL cholesterol, is also frequently seen and contributes to a higher risk of atherosclerosis. Dyslipidemia not only worsens glycemic control but also increases the risk of cardiovascular complications and liver-related conditions such as nonalcoholic fatty liver disease (NAFLD). NAFLD is considered a hepatic complication of insulin resistance and is frequently associated with T2DM and dyslipidemia.
About MediciNova
MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.
Forward-Looking Statements
Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166 and MN-001. These forward-looking statements may be preceded by, followed by, or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166 and MN-001, and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2024 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.
INVESTOR CONTACT :
David H. Crean, Ph.D.
Chief Business Officer
MediciNova, Inc
info@medicinova.com
FAQ**
How does the completion of patient enrollment in the Phase 2 trial for MN-001 (tipelukast) signal potential market developments for MediciNova Inc. MNOV in treating hypertriglyceridemia and NAFLD due to T2DM?
What are the anticipated implications for MediciNova Inc. MNOV's stock performance based on the expected top-line data release in summer 20for the MN-001 study?
In what ways could the results of the MN-001 (tipelukast) trial influence MediciNova Inc. MNOV's ability to secure future partnerships or funding?
How do MN-001's mechanisms of action enhance its therapeutic potential for conditions associated with T2DM, and what does this mean for MediciNova Inc. MNOV's competitive positioning in the biopharmaceutical market?
**MWN-AI FAQ is based on asking OpenAI questions about MediciNova Inc. (NASDAQ: MNOV).
NASDAQ: MNOV
MNOV Trading
1.45% G/L:
$1.40 Last:
8,403 Volume:
$1.41 Open:
